Sarepta Therapeutics, Inc., based in Cambridge, MA, is a leader in the development of innovative oligonucleotide therapeutics, focusing on addressing genetic diseases, particularly muscular dystrophy. The company specializes in advanced technologies such as antisense delivery and exon skipping, utilizing oligonucleotide analogues and peptide conjugates to enhance therapeutic efficacy. With a commitment to pioneering treatments, Sarepta is at the forefront of research aimed at transforming the lives of patients with rare genetic disorders.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

127 Patents

#22 in Cambridge, MA

#164 in Massachusetts

#3,054 in US

#6,324 in the World

Cambridge, MA, United States of America

Sarepta Therapeutics, Inc.

Forward Citations = 1,698

73 inventors:

Gunnar J Hanson (41 out of 183 patents)

Patrick L Iversen (36 out of 95 patents)

Dwight D Weller (27 out of 61 patents)

4. Ryszard M Kole (23 out of 29 patents)

5. Richard Keith Bestwick (17 out of 36 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sarepta Therapeutics, Inc.. Retrieved from https://idiyas.com/company/sarepta-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

11 patents (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

41 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]